AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04357730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase 50 MG [Activase]
Description: Patients randomized to Alteplase-50 group will receive 50 mg of Alteplase intravenous bolus administration over 2 hours, given as a 10 mg push followed by the remaining 40 mgs over a total time of 2 hrs. Immediately following the Alteplase infusion, 5000 units (U) of unfractionated heparin (UFH) will be delivered and the heparin drip will be continued to maintain the activated partial thromboplastin time (aPTT) at 60-80sec (2.0 to 2.5 times the upper limit of normal). Re-bolusing of Alteplase, at the same dose, is permitted in the Alteplase-50 intervention group in those patients who show an initial transient response (>20% improvement of PaO2/FiO2 over pre-infusion of Alteplase at any of the measurements at 2, 6, 12 or 18 hours, but \<50% improvement of PaO2/FiO2 at 24 hours after randomization); the repeat dose will be given between 24 and 36 hours after the initial Alteplase administration.
Study NCT04357730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase 50 MG [Activase]
Description: wed by the remaining 40 mgs over a total time of 2 hrs. Immediately following this initial Alteplase infusion, we will initiate a drip of 2 mg/hr Alteplase over the ensuing 24 hours (total 48 mg infusion) accompanied by an infusion of 500 units per hour (U/hr) heparin during the Alteplase drip. After this, heparin dose will be increased slowly to maintain aPTT between 60 and 80 sec, titrated per attending's discretion.
Study NCT01723293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: The physical conditioning program included a total of three 55-60 minute sessions per week. Pregnant women started in 9-12 weeks and finished in 38-40 weeks, therefore, an average of 85 training sessions were planned for each participant. All subjects wore a heart rate (HR) monitor (Polar FT7, Finland) during the training sessions to ensure that the exercise intensity was light to moderate.~Each session included a 25-minutes of aerobic exercise, 10-minutes of strength exercise and balance exercise as well, and 10-minutes of pelvic floor muscles training.
Study NCT04746586 — intervention group
Intervention type: OTHER
Intervention: Circulating MiRNA indentification
Description: Identification of circulating miRNA useful to discriminate between worsening and stable forms of AIS
Study NCT00345046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate
Description: Dosed four times daily decreasing to once daily over four weeks.
Study NCT04681794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise-based intervention
Description: MayoP4 is a 15-minute warmup with 4 different components of exercise: balance, posture, jumping/hopping, and movement-based mindfulness.
Study NCT01754051 — intervention group
Intervention type: DEVICE
Intervention: PC 400 coils
Study NCT04383067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Patient with metastatic urothelial carcinoma will undergo a autologous lymphocyte transplantation. Patient will undergo surgery to remove either the primary tumor or a tumor metastasis. The cells collected in this surgey will be cultured and reintroduced to the patient. Following the cell infusion, patient will receive a high-dose bolus of IL-2.
Study NCT00685269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone
Description: Eszopiclone 3 mg QD
Study NCT00685269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT01074463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole Dihydrochloride
Description: 0.25 mg Tablet
Study NCT01074463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole Dihydrochloride
Description: 0.25 mg Tablet
Study NCT04495257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg intravenously (IV) every 3 weeks for the first 4 treatments and then will be given at 360mg every 3 weeks thereafter
Study NCT04495257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1mg/kg intravenously (IV) every 3 weeks for a total of 4 treatments
Study NCT04495257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: APX005M 0.3mg/kg intravenously (IV) every 3 weeks
Study NCT04186988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Ara-G
Description: Given IV
Study NCT03401021 — intervention group
Intervention type: OTHER
Intervention: Questionnaires set
Description: Participants will be asked to respond to the demographic information sheet, Smoking characteristics sheet, the Fagerstrom Test of Nicotine Dependence, the Transtheoretical Model (TTM) variables, Smoking Self-efficacy Questionnaire (SEQ-12), Family Adaptation, Partnership, Growth, Affection, and Resolve (Family APGAR), and a smoking hazard questionnaire.
Study NCT01205061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emervel Deep Lidocaine
Description: 20 mg/mL + 0.3% lidocaine
Study NCT03355651 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PROGEN
Description: Dietary supplement based on plasma proteins, hydrolyzed collagen, a complex of Hyaluronic Acid - Chondroitin Sulfate (HC-15), and vitamin C
Study NCT02855333 — intervention group
Intervention type: OTHER
Intervention: EORTC and QLQ-C30 / QLQ-OES24 questionnaire
Description: EORTC and QLQ-C30 / QLQ-OES24 questionnaire was sent to patients to asses QoL after MER or CON procedure
Study NCT01138033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256098
Description: GSK2256098 is a potent focal adhesion kinase inhibitor that will be administered orally as 20, 100 or 250 mg capsules. The starting dose in Part 1 is 80 mg twice daily. The dose will continue to be increased until the maximum tolerated dose is identified.
Study NCT02820987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEROPENEM
Description: Administration of MEROPENEM according to a protocol of extended infusion defining dose and duration of infusion.
Study NCT00298051 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping
Study NCT00863603 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: oxygen
Description: 5 Liter/minute by nasal cannula for 6 wks
Study NCT04383067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proleukin
Description: high-dose (720,000 IU/kg) IL-2 will be administered every 8 hours, to tolerance. A maximum of 10 doses will be administered
Study NCT03150875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI308
Description: Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.
Study NCT02820987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PIPERACILLIN-TAZOBACTAM
Description: Administration of PIPERACILLIN-TAZOBACTAM according to a protocol of continuous infusion defining dose and duration of infusion.
Study NCT02820987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEFEPIME
Description: Administration of CEFEPIME according to a protocol of continuous infusion defining dose and duration of infusion.
Study NCT03150875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: As 2nd line treatment to subjects with squamous NSCLC
Study NCT04250155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb24306
Description: Participants will receive intravenous (IV) XmAb24306.
Study NCT04250155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive IV XmAb24306 followed by IV atezolizumab
Study NCT04250155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XmAb24306
Description: Participants will receive IV XmAb24306 followed by IV atezolizumab.
Study NCT01322867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam tablet
Description: 0,25 mg oral tablets given once
Study NCT01322867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alprazolam oral solution
Description: 0,75 mg/ml Oral Solution (Drops) given once
Study NCT00670202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil Hydrochloride
Description: Fasudil 40 mg three times a day x 14 days
Study NCT00670202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo oral tablet manufactured to mimic fasudil three times a day x 14 days
Study NCT03357718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex
Description: 2 µg/kg oral
Study NCT03357718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 0.5 mg/kg
Study NCT04380090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propylene Glycol
Description: Patients in the propylene glycol arm will receive one standard dose of the drug on postoperative day one prior to discharge with the aim of decreasing rates of postoperative constipation for patients following single total knee replacement surgery
Study NCT04380090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docusate Sodium
Description: Patients in the docusate sodium arm are receiving the current standard of care for prevention of postoperative constipation following single total knee replacement surgery, docusate sodium one pill twice a day by mouth for 28 days
Study NCT03392987 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OTL-200
Description: OTL-200 is an autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human ARSA cDNA sequence
Study NCT00702533 — intervention group
Intervention type: DEVICE
Intervention: Pentagastrin Injection BP
Study NCT01205061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvederm Ultra Plus
Description: 24mg/mL
Study NCT01520701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bandage skin Hydrotac®
Description: Patients randomized to the arm with bandage skin will benefit from the application of the bandage skin hydrogel (Hydrotac®) at least 5 hours per day for the duration of treatment (the first day last day of radiotherapy).
Study NCT03629756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant
Description: Etrumadenant is an A2aR and A2bR antagonist.
Study NCT01520701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ialuset®
Description: Patients randomized to receive reference of the application of cervical Ialuset® on skin throughout the treatment period (the first day to last day of radiotherapy).
Study NCT03327220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iovera°
Description: The iovera° device applies cold to a target nerve to cause a temporary peripheral nerve block based on a process called Wallerian degeneration (2nd degree axonotmesis) without disrupting connective nerve tissue.
Study NCT03960411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 100Mg Capsule
Description: Doxycycline capsule
Study NCT03960411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Capsule manufactured to mimic doxycycline 100 mg capsule
Study NCT01686425 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous transhepatic cholangiography vs. endoscopic biliary drainage
Description: Percutaneous transhepatic cholangiography biliary drainage is compared tot endoscopic biliary drainage in the management of malignant biliary obstruction not amenable to ERCP
Study NCT01693341 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care-giver mediated training
Description: A physical therapist visited each subject and the caregiver (of the intervention group) once weekly for about 90 min/session to teach patient-skills and caregiver-skills. The therapist first reviewed the condition of each patient and planned patient-specific training programs, continuously performed 12 weeks.
Study NCT00551148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: oral 15 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
Study NCT00551148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: oral 30 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
Study NCT00551148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: oral 5 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
Study NCT00551148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0200390
Description: oral 60 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
Study NCT00551148 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
Study NCT03425006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: a JAK 1 selective small molecule inhibitor
Study NCT03425006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: a highly selective humanized monoclonal antibody (mAb)
Study NCT02383654 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autologous Adipose-Tissue Derived Stem Cells
Description: 1. Intravenous and Intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells~2. Patient will receive brain implantation of approximately 100 -400million Autologous Adipose-Tissue Derived Stem Cells.~Patient will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice , before brain implantation, and will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice, after brain implantation .
Study NCT00646763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF, GM-CSF administered at extremities
Description: Injection site Extremities: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a twice daily schedule of G-CSF/GM-CSF until stem cell collection is complete.
Study NCT00646763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF and GMCSF administered at abdomen
Description: Injection site Abdomen: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a BID schedule of G-CSF/GM-CSF until stem cell collection is complete.
Study NCT01676753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinaciclib
Description: Given IV
Study NCT01676753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT01076868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Primaquine x 14 days
Study NCT01345513 — intervention group
Intervention type: OTHER
Intervention: Sample Collection for Genome-Wide Sequencing
Description: Collection of archival tumor tissue, fresh tumor biopsy, blood sample, and pleural effusion (if available)or ascites (if available)
Study NCT02899650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: acute downhill running
Study NCT00432471 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optical Imaging
Description: Imaging using the multispectral digital microscope (MDM), a system that shines different colors of light on the skin and takes pictures of fluorescence and reflectance on the skin area.
Study NCT04358133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhydrate de morphine
Description: The experimental group will receive an intravenous titration of morphine followed by a subcutaneous administration of morphine hydrochloride for 24 hours according to a predefined protocol
Study NCT04358133 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0,9%,
Description: The control group will receive placebo NaCl 0.9% administered according to the same protocol as the experimental arm
Study NCT03629756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is a fully human anti-PD-1 monoclonal antibody.
Study NCT03696953 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Florajen3
Description: Probiotic combination product One capsule daily by mouth.
Study NCT01014793 — intervention group
Intervention type: DRUG
Intervention: cabergoline
Description: cabergoline doses were increased at 6-week intervals, starting at 1.0mg/week followed by 2.0 and 3.5mg/week. Hormonal evaluations (IGF-I, GH and PRL) started before the first dose and were repeated at 6-week intervals after each cabergoline dose and after cabergoline withdrawal
Study NCT01372085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2584702 Reference Formulation
Description: Administered orally
Study NCT03239743 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Child will wear and interact with virtual reality headset while waiting for surgery.
Study NCT03239743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Child will receive Midazolam to help with pre-operative anxiety prior to surgery
Study NCT02816008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation training with RGS in the clinic
Description: Daily cognitive training with the Rehabilitation Gaming System (RGS) in the clinic during 6 weeks (5 days per week a 30 minutes).
Study NCT02816008 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive/conventional cognitive training at home.
Description: Daily conventional cognitive rehabilitation at home as recommended by the neurologist during 6 weeks (5 days per week a 30 minutes).
Study NCT03938623 — intervention group
Intervention type: OTHER
Intervention: Training
Description: Teaching general practitioners to use the patient-centered approach when suggesting colorectal cancer screening
Study NCT03850314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycine
Description: Glycine powder to be dissolved in water.
Study NCT02360176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy single port
Description: Bariatric surgery: one incision of 2.5 to 3 cm
Study NCT02360176 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleeve gastrectomy multi trocar
Description: Bariatric surgery: 4 to 7 incisions of 1 to 2 cm
Study NCT02478203 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: videolaryngoscope for difficult airway
Study NCT02478203 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Airtraq
Description: videolaryngoscope for difficult airway
Study NCT01302093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril Film-Coated Tablet (FCT)
Description: A single 100 mg dose of an experimental Racecadotril FCT administered orally with 240 ml of water, with a 7- day washout between visits
Study NCT01372085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2584702 Test Formulation
Description: Administered orally
Study NCT01372085 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01372085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT01302093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racecadotril Capsule
Description: A single 100 mg dose of a marketed Racecadotril capsule administered orally with 240 ml of water, with a 7-day washout between visits
Study NCT01479699 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive leaf extract capsules
Description: Four capsules taken at baseline each containing 4mg oleuropein
Study NCT02478203 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Description: videolaryngoscope for difficult airway
Study NCT02478203 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Glidescope
Description: videolaryngoscope for difficult airway
Study NCT02478203 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: direct laryngoscopy
Description: gold standart for intubation
Study NCT02478203 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: direct laryngoscopy
Description: gold standart for intubation
Study NCT01531543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V.A.C.- Vacuum assisted closure laparostomy (KCI)
Description: Primary Vacuum Assisted Closure (V.A.C.)laparostomy was indicated after surgery in patients with severe peritonitis. VAC laparostomy was performed using sandwich technique (semi-permeable foil - intraabdominal foam - dynamic sutura of the fascia - foam inserted subcutaneously - non-permeable foil) and connected to the active suction of 125mmHg.
Study NCT04261907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC09/ritonavir group
Description: ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment